An Open-label, Prospective Multicenter Study to Assess the Pharmacokinetics, Tolerability, Safety and Efficacy of the Pediatric Formulation of Bosentan Two Versus Three Times a Day in Children With Pulmonary Arterial Hypertension

Trial Profile

An Open-label, Prospective Multicenter Study to Assess the Pharmacokinetics, Tolerability, Safety and Efficacy of the Pediatric Formulation of Bosentan Two Versus Three Times a Day in Children With Pulmonary Arterial Hypertension

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Jul 2017

At a glance

  • Drugs Bosentan (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Pharmacokinetics; Registrational
  • Acronyms FUTURE 3
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 18 Feb 2017 Results published in the British Journal of Clinical Pharmacology.
    • 16 Apr 2014 New trial record
    • 09 Oct 2013
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top